Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Organ transplant patients with infective endocarditis are at serious risk. A large French multicenter study found that solid organ and stem cell transplant recipients with infective endocarditis (IE) had a 69% higher 1-year all-cause mortality compared to non-transplant patients. They also showed a distinct infection profile — with more fungal, enterococcal, and coagulase-negative staph infections — signaling that IE in this population is a marker of deep, sustained vulnerability.
Transplant patients battling infective endocarditis face a much steeper uphill climb than the general population. A retrospective study across 27 French hospitals found that solid organ and haematopoietic stem cell transplant recipients diagnosed with IE had a 69% higher risk of dying within one year compared to matched non-transplant controls. Notably, this elevated risk didn't show up at 90 days — suggesting that the long-term toll of IE in immunocompromised transplant patients is uniquely severe.
The bugs causing IE in transplant recipients also looked different. These patients were more likely to be infected by coagulase-negative staphylococci, Enterococcus species, fungi, and non-HACEK gram-negative bacilli — while streptococcal infections, more common in the general population, were less frequent. Fungal IE was especially prevalent after thoracic organ and stem cell transplants, and within the first year post-transplant.
Key Takeaways:
Why it matters: For clinicians managing transplant patients, IE isn't just another infection — it's a signal of sustained vulnerability. Early recognition of atypical pathogens and aggressive management of modifiable risk factors could be key to improving outcomes in this high-risk group.
